The tumor necrosis factor superfamily of cytokines in the inflammatory myopathies: Potential targets for therapy

Clinical and Developmental Immunology

Volumn 2012, Issue , 2012, Pages

  De Paepe, Boel ^a   Creus, Kim K ^a   De Bleecker, Jan L ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; APRIL PROTEIN; B CELL ACTIVATING FACTOR; CD137 LIGAND; CD30 LIGAND; CD40 LIGAND; CD70 ANTIGEN; CERTOLIZUMAB PEGOL; CYTOKINE; ETANERCEPT; FAS LIGAND; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; HERPESVIRUS ENTRY MEDIATOR LIGAND; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; LYMPHOTOXIN ALPHA BETA; OSTEOCLAST DIFFERENTIATION FACTOR; OX40 LIGAND; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR LIKE WEAK INDUCER OF APOPTOSIS; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL GROWTH INHIBITOR; ANTIINFLAMMATORY AGENT; MONOCLONAL ANTIBODY;

ANTIBODY PRODUCTION; B LYMPHOCYTE ACTIVATION; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CYTOKINE PRODUCTION; DERMATOMYOSITIS; ENZYME ACTIVITY; HUMAN; IMMUNE RESPONSE; INCLUSION BODY MYOSITIS; MYOSITIS; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); POLYMYOSITIS; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION; DRUG ANTAGONISM; IMMUNOLOGY; METABOLISM; PHYSIOLOGY;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; HUMANS; MYOSITIS; TUMOR NECROSIS FACTOR-ALPHA; TUMOR NECROSIS FACTORS;

EID: 84855182041     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2012/369432     Document Type: Review

References (99)

1. Dalakas M. C., Hohlfeld R., Polymyositis and dermatomyositis The Lancet 2003 362 9388 971 982 (Pubitemid 37159295)
2. Askanas V., Engel W. K., Inclusion-body myositis: muscle-fiber molecular pathology and possible pathogenic significance of its similarity to Alzheimer's and Parkinson's disease brains Acta Neuropathologica 2008 116 6 583 595
3. Mammen A. L., Dermatomyositis and polymyositis: clinical presentation, autoantibodies, and pathogenesis Annals of the New York Academy of Sciences 2010 1184 134 153
4. Mammen A. L., Autoimmune myopathies: autoantibodies, phenotypes and pathogenesis Nature Reviews Neurology 2011 7 6 343 354
5. Salajegheh M., Lam T., Greenberg S. A., Autoantibodies against a 43 kDa muscle protein in inclusion body myositis PLoS ONE 2011 6 5, article e20266
6. Lundberg I., Ulfgren A. K., Nyberg P., Andersson U., Klareskog L., Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies Arthritis and Rheumatism 1997 40 5 865 874 (Pubitemid 27200003)
7. Greenberg S. A., Sanoudou D., Haslett J. N., Kohane I. S., Kunkel L. M., Beggs A. H., Amato A. A., Molecular profiles of inflammatory myopathies Neurology 2002 59 8 1170 1182 (Pubitemid 35192386)
8. Cappelletti C., Baggi F., Zolezzi F., Biancolini D., Beretta O., Severa M., Coccia E. M., Confalonieri P., Morandi L., Mora M., Mantegazza R., Bernasconi P., Type I interferon and Toll-like receptor expression characterizes inflammatory myopathies Neurology 2011 76 24 2079 2088
9. Ware C. F., The TNF superfamily-2008 Cytokine and Growth Factor Reviews 2008 19 3-4 183 186 (Pubitemid 351794570)
10. Tartaglia L. A., Pennica D., Goeddel D. V., Ligand passing: the 75-kDa tumor necrosis factor (TNF) receptor recruits TNF for signaling by the 55-kDa TNF receptor Journal of Biological Chemistry 1993 268 25 18542 18548 (Pubitemid 23273787)
11. Bhatnagar S., Panguluri S. K., Gupta S. K., Dahiya S., Lundy R. F., Kumar A., Tumor necrosis factor- regulates distinct molecular pathways and gene networks in cultured skeletal muscle cells PLoS ONE 2010 5 10, article e13262
12. De Bleecker J. L., Meire V. I., Declercq W., Van Aken E. H., Immunolocalization of tumor necrosis factor-alpha and its receptors in inflammatory myopathies Neuromuscular Disorders 1999 9 4 239 246 (Pubitemid 29287259)
13. Kuru S., Inukai A., Liang Y., Doyu M., Takano A., Sobue G., Tumor necrosis factor- expression in muscles of polymyositis and dermatomyositis Acta Neuropathologica 2000 99 5 585 588 (Pubitemid 30201324)
14. Tews D. S., Goebel H. H., Cytokine expression profile in idiopathic inflammatory myopathies Journal of Neuropathology and Experimental Neurology 1996 55 3 342 347 (Pubitemid 26085583)
15. Gabay C., Gay-Croisier F., Roux-Lombard P., Meyer O., Maineti C., Guerne P. A., Vischer T., Dayer J. M., Elevated serum levels of interleukin-1 receptor antagonist in polymyositis/dermatomyositis: a biologic marker of disease activity with a possible role in the lack of acute-phase protein response Arthritis and Rheumatism 1994 37 12 1744 1751 (Pubitemid 24371875)
16. Fedczyna T. O., Lutz J., Pachman L. M., Expression of TNFalpha by muscle fibers in biopsies from children with untreated juvenile dermatomyositis: association with the TNFalpha-308A allele Clinical Immunology 2001 100 2 236 239
17. Mamyrova G., O'Hanlon T. P., Sillers L., Malley K., James-Newton L., Parks C. G., Cooper G. S., Pandey J. P., Miller F. W., Rider L. G., Cytokine gene polymorphisms as risk and severity factors for juvenile dermatomyositis Arthritis and Rheumatism 2008 58 12 3941 3950
18. Collins R. A., Grounds M. D., The role of tumor necrosis factor-alpha (TNF- ) in skeletal muscle regeneration: studies in TNF- (-/-) and TNF- (-/-)/LT- (-/-) mice Journal of Histochemistry and Cytochemistry 2001 49 8 989 1001 (Pubitemid 32675006)
19. Riley P., Mccann L. J., Maillard S. M., Woo P., Murray K. J., Pilkington C. A., Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis Rheumatology 2008 47 6 877 880 (Pubitemid 351796377)
20. Dastmalchi M., Grundtman C., Alexanderson H., Mavragani C. P., Einarsdottir H., Barbasso Helmers S., Elvin K., Crow M. K., Nennesmo I., Lundberg I. E., A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies Annals of the Rheumatic Diseases 2008 67 12 1670 1677
21. Hengstman G. J. D., Van Den Hoogen F. H. J., Barrera P., Netea M. G., Pieterse A., Van De Putte L. B. A., Van Engelen B. G. M., Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor-alpha: preliminary observations European Neurology 2003 50 1 10 15 (Pubitemid 36736963)
22. Hengstman G. J. D., De Bleecker J. L., Feist E., Vissing J., Denton C. P., Manoussakis M. N., Slott Jensen H., Van Engelen B. G. M., Van Den Hoogen F. H. J., Open-label trial of anti-TNF- in dermato- and polymyositis treated concomitantly with methotrexate European Neurology 2008 59 3-4 159 163 (Pubitemid 351301260)
23. Hengstman G. J. D., Van Den Hoogen F. H. J., Van Engelen B. G. M., Treatment of dermatomyositis and polymyositis with anti-tumor necrosis factor- : long-term follow-up European Neurology 2004 52 1 61 63 (Pubitemid 39077819)
24. Labioche L., Liozon E., Weschler B., Loustaud-Ratti V., Soria P., Vidal E., Refractory polymyositis responding in infliximab: extended follow-up Rheumatology 2004 43 4 531 532 (Pubitemid 38489380)
25. Efthimiou P., Schwartzman S., Kagen L. J., Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients Annals of the Rheumatic Diseases 2006 65 9 1233 1236 (Pubitemid 44277404)
26. Sprott H., Glatzel M., Mitchel B. A., Treatment of myositis with etanercept/Enbrel, a recombinant human soluble fusion protein of TNF- type II receptor and IgG1 Rheumatology 2004 43 4 524 526 (Pubitemid 38489376)
27. Liang Y., Inukai A., Kuru S., Kato T., Doyu M., Sobue G., The role of lymphotoxin in pathogenesis of polymyositis Acta Neuropathologica 2000 100 5 521 527
28. De Padilla C. M. L., Vallejo A. N., Lacomis D., Mcnallan K., Reed A. M., Extranodal lymphoid microstructures in inflamed muscle and disease severity of new-onset Juvenile dermatomyositis Arthritis and Rheumatism 2009 60 4 1160 1172
29. Creus K. K., De Paepe B., Weis J., De Bleecker J. L., The multifaceted character of lymphotoxin in inflammatory myopathies. Submitted
30. Chiang E. Y., Kolumam G. A., Yu X., Francesco M., Ivelja S., Peng I., Gribling P., Shu J., Lee W. P., Refino C. J., Balazs M., Paler-Martinez A., Nguyen A., Young J., Barck K. H., Carano R. A. D., Ferrando R., Diehl L., Chatterjea D., Grogan J. L., Targeted depletion of lymphotoxin- -expressing T H 1 and T H 17 cells inhibits autoimmune disease Nature Medicine 2009 15 7 766 773
31. Fava R. A., Notidis E., Hunt J., Szanya V., Ratcliffe N., Ngam-ek A., De Fougerolles A. R., Sprague A., Browning J. L., A role for the lymphotoxin/LIGHT axis in the pathogenesis of murine collagen-induced arthritis Journal of Immunology 2003 171 1 115 126 (Pubitemid 36745279)
32. Dohi T., Rennert P. D., Fujihashi K., Abrogation of lymphotoxin-beta receptor signal pathway inhibits colonic patch genesis and Th2-type colitis The FASEB Journal 2000 14 6 975
33. Takemura S., Braun A., Crowson C., Kurtin P. J., Cofield R. H., O'Fallon W. M., Goronzy J. J., Weyand C. M., Lymphoid neogenesis in rheumatoid synovitis Journal of Immunology 2001 167 2 1072 1080 (Pubitemid 32660867)
34. Croft M., So T., Duan W., Soroosh P., The significance of OX40 and OX40L to T-cell biology and immune disease Immunological Reviews 2009 229 1 173 191
35. Tateyama M., Fujihara K., Ishii N., Sugamura K., Onodera Y., Itoyama Y., Expression of OX40 in muscles of polymyositis and granulomatous myopathy Journal of the Neurological Sciences 2002 194 1 29 34 (Pubitemid 34051552)
36. Totsuka T., Kanai T., Uraushihara K., Iiyama R., Yamazaki M., Akiba H., Yagita H., Okumura K., Watanabe M., Therapeutic effect of anti-OX40l and anti-TNF- MAbs in a murine model of chronic colitis American Journal of Physiology 2003 284 4 G595 G603
37. Yoshioka T., Nakajima A., Akiba H., Ishiwata T., Asano G., Yoshino S. I., Yagita H., Okumura K., Contribution of OX40/OX40 ligand interaction to the pathogenesis of rheumatoid arthritis European Journal of Immunology 2000 30 10 2815 2823
38. Henn V., Slupsky J. R., Grfe M., Anagnostopoulos I., Frster R., Mller-Berghaus G., Kroczek R. A., CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells Nature 1998 391 6667 591 594 (Pubitemid 28157601)
39. Sugiura T., Kawaguchi Y., Harigai M., Takagi K., Ohta S., Fukasawa C., Hara M., Kamatani N., Increased CD40 expression on muscle cells of polymyositis and dermatomyositis: role of CD40-CD40 ligand interaction in IL-6, IL-8, IL-15, and monocyte chemoattractant protein-1 production Journal of Immunology 2000 164 12 6593 6600 (Pubitemid 30408846)
40. Tellander A. C., Michalsson E., Brunmark C., Andersson M., Potent adjuvant effect by anti-CD40 in collagen-induced arthritis. Enhanced disease is accompanied by increased production of collagen type-II reactive IgG2a and IFN- Journal of Autoimmunity 2000 14 4 295 302
41. Durie F. H., Fava R. A., Foy T. M., Aruffo A., Ledbetter J. A., Noelle R. J., Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40 Science 1993 261 5126 1328 1330 (Pubitemid 24081170)
42. Maerten P., Geboes K., Hertogh G. D., Shen C., Cadot P., Bullens D. M. A., Assche G. V., Penninckx F., Rutgeerts P., Ceuppens J. L., Functional expression of 4-1BB (CD137) in the inflammatory tissue in Crohn's disease Clinical Immunology 2004 112 3 239 246 (Pubitemid 39078699)
43. Kalunian K. C., Davis J. C., Merrill J. T., Totoritis M. C., Wofsy D., Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial Arthritis and Rheumatism 2002 46 12 3251 3258 (Pubitemid 35453534)
44. Kondo M., Murakawa Y., Harashima N., Kobayashi S., Yamaguchi S., Harada M., Roles of proinflammatory cytokines and the Fas/Fas ligand interaction in the pathogenesis of inflammatory myopathies Immunology 2009 128 1 e589 e599
45. De Bleecker J. L., Meire V. I., Van Walleghem I. E., Groessens I. M., Schrder J. M., Immunolocalization of Fas and Fas ligand in inflammatory myopathies Acta Neuropathologica 2001 101 6 572 578 (Pubitemid 32684755)
46. Behrens L., Bender A., Johnson M. A., Hohlfeld R., Cytotoxic mechanisms in inflammatory myopathies. Co-expression of Fas and protective Bcl-2 in muscle fibres and inflammatory cells Brain 1997 120 6 929 938 (Pubitemid 27259544)
47. Fyhr I. M., Oldfors A., Upregulation of Fas/Fas ligand in inclusion body myositis Annals of Neurology 1998 43 1 127 130 (Pubitemid 28124660)
48. Inukai A., Kobayashi Y., Ito K., Doyu M., Takano A., Honda H., Sobue G., Expression of Fas antigen is not associated with apoptosis in human myopathies Muscle and Nerve 1997 20 6 702 709 (Pubitemid 27197723)
49. Nozawa K., Kayagaki N., Tokano Y., Yagita H., Okumura K., Hasimoto H., Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic diseases Arthritis and Rheumatism 1997 40 6 1126 1129 (Pubitemid 27242300)
50. Antiga E., Kretz C. C., Klembt R., Massi D., Ruland V., Stumpf C., Baroni G., Hartmann M., Hartschuh W., Volpi W., Del Bianco E., Enk A., Fabbri P., Krammer P. H., Caproni M., Kuhn A., Characterization of regulatory T cells in patients with dermatomyositis Journal of Autoimmunity 2010 35 4 342 350
51. Guéry L., Batteux F., Bessis N., Breban M., Boissier M. C., Fournier C., Chiocchia G., Expression of Fas ligand improves the effect of IL-4 in collagen-induced arthritis European Journal of Immunology 2000 30 1 308 315 (Pubitemid 30011793)
52. Hashimoto H., Tanaka M., Suda T., Tomita T., Hayashida K., Takeuchi E., Kaneko M., Takano H., Nagata S., Ochi T., Soluble fas ligand in the joints of patients with rheumatoid arthritis and osteoarthritis Arthritis and Rheumatism 1998 41 4 657 662 (Pubitemid 28214983)
53. Oelke K., Lu Q., Richardson D., Wu A., Deng C., Hanash S., Richardson B., Overexpression of CD70 and overstimulation of IgG synthesis by lupus T cells and T cells treated with DNA methylation inhibitors Arthritis and Rheumatism 2004 50 6 1850 1860 (Pubitemid 38725098)
54. Oflazoglu E., Boursalian T. E., Zeng W., Edwards A. C., Duniho S., McEarchern J. A., Law C. L., Gerber H. P., Grewal I. S., Blocking of CD27-CD70 pathway by anti-CD70 antibody ameliorates joint disease in murine collagen-induced arthritis Journal of Immunology 2009 183 6 3770 3777
55. Danielsson O., Nilsson C., Lindvall B., Ernerudh J., Expression of apoptosis related proteins in normal and diseased muscle: a possible role for Bcl-2 in protection of striated muscle Neuromuscular Disorders 2009 19 6 412 417
56. Cretney E., McQualter J. L., Kayagaki N., Yagita H., Bernard C. C. A., Grewal I. S., Ashkenazi A., Smyth M. J., TNF-related apoptosis-inducing ligand (TRAIL)/Apo2L suppresses experimental autoimmune encephalomyelitis in mice Immunology and Cell Biology 2005 83 5 511 519 (Pubitemid 41805753)
57. Wandinger K. P., Lnemann J. D., Wengert O., Bellmann-Strobl J., Aktas O., Weber A., Grundstrm E., Ehrlich S., Wernecke K. D., Volk H. D., Zipp F., TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis The Lancet 2003 361 9374 2036 2043 (Pubitemid 36695046)
58. Kartsogiannis V., Zhou H., Horwood N. J., Thomas R. J., Hards D. K., Quinn J. M. W., Niforas P., Ng K. W., Martin T. J., Gillespie M. T., Localization of RANKL (receptor activator of NF B ligand) mRNA and protein in skeletal and extraskeletal tissues Bone 1999 25 5 525 534 (Pubitemid 29469458)
59. Page G., Miossec P., RANK and RANKL expression as markers of dendritic cell-T cell interactions in paired samples of rheumatoid synovium and lymph nodes Arthritis and Rheumatism 2005 52 8 2307 2312 (Pubitemid 41117414)
60. Bekker P. J., Holloway D. L., Rasmussen A. S., Murphy R., Martin S. W., Leese P. T., Holmes G. B., Dunstan C. R., DePaoli A. M., A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women Journal of Bone and Mineral Research 2005 20 12 2275 2282
61. Mackay F., Schneider P., Rennert P., Browning J., BAFF and APRIL: a tutorial on B cell survival Annual Review of Immunology 2003 21 231 264 (Pubitemid 37174532)
62. Matsushita T., Hasegawa M., Yanaba K., Kodera M., Takehara K., Sato S., Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes Arthritis and Rheumatism 2006 54 1 192 201 (Pubitemid 43122202)
63. Krytfkov O., Vallerskog T., Barbasso Helmers S., Mann H., Ptov I., Blek J., Malmstrm V., Trollmo C., Vencovsk J., Lundberg I. E., Increased serum levels of B cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies Annals of the Rheumatic Diseases 2009 68 6 836 843
64. Szodoray P., Alex P., Knowlton N., Centola M., Dozmorov I., Csipo I., Nagy A. T., Constantin T., Ponyi A., Nakken B., Danko K., Idiopathic inflammatory myopathies, signified by distinctive peripheral cytokines, chemokines and the TNF family members B-cell activating factor and a proliferation inducing ligand Rheumatology 2010 49 10 1867 1877
65. Salajegheh M., Pinkus J. L., Amato A. A., Morehouse C., Jallal B., Yao Y., Greenberg S. A., Permissive environment for B-cell maturation in myositis muscle in the absence of B-cell follicles Muscle and Nerve 2010 42 4 576 583
66. Baek A. H., Suh G. I., Hong J. M., Suh B. C., Shim D. S., Choi Y. C., The increased expression of B cell activating factor (BAFF) in patients with dermatomyositis Neuromuscular Disorders 2010 20 9-10 634
67. Lundberg I. E., Barbasso Helmers S., The type I interferon system in idiopathic inflammatory myopathies Autoimmunity 2010 43 3 239 243
68. Greenberg S. A., Bradshaw E. M., Pinkus J. L., Pinkus G. S., Burleson T., Due B., Bregoli L. S., O'Connor K. C., Amato A. A., Plasma cells in muscle in inclusion body myositis and polymyositis Neurology 2005 65 11 1782 1787
69. Yoo D. H., Anticytokine therapy in systemic lupus erythematosus Lupus 2010 19 12 1460 1467
70. Dai Z., Li Q., Wang Y., Gao G., Diggs L. S., Tellides G., Lakkis F. G., CD4+CD25+ regulatory T cells suppress allograft rejection mediated by memory CD8+ T cells via a CD30-dependent mechanism Journal of Clinical Investigation 2004 113 2 310 317 (Pubitemid 38544215)
71. Sun X., Yamada H., Shibata K., Muta H., Tani K., Podack E. R., Iwakura Y., Yoshikai Y., CD30 ligand is a target for a novel biological therapy against colitis associated with Th17 responses Journal of Immunology 2010 185 12 7671 7680
72. Gerli R., Muscat C., Bistoni O., Falini B., Tomassini C., Agea E., Tognellini R., Biagini P., Bertotto A., High levels of the soluble form of CD30 molecule in rheumatoid arthritis (RA) are expression of CD30+ T cell involvement in the inflamed joints Clinical and Experimental Immunology 1995 102 3 547 550 (Pubitemid 26013219)
73. Caligaris-Cappio F., Bertero M. T., Converso M., Stacchini A., Vinante F., Romagnani S., Pizzolo G., Circulating levels of soluble CD30, a marker of cells producing Th2-type cytokines, are increased in patients with systemic lupus erythematosus and correlate with disease activity Clinical and Experimental Rheumatology 1995 13 3 339 343
74. Jung H. W., Choi S. W., Choi J. I. L., Kwon B. S., Serum concentrations of soluble 4-1BB, and 4-1BB ligand correlated with the disease severity in rheumatoid arthritis Experimental and Molecular Medicine 2004 36 1 13 22 (Pubitemid 38379632)
75. Seo S. K., Choi J. H., Kim Y. H., Kang W. J., Park H. Y., Suh J. H., Choi B. K., Vinay D. S., Kwon B. S., 4-1BB-mediated immunotherapy of rheumatoid arthritis Nature Medicine 2004 10 10 1088 1094 (Pubitemid 39424870)
76. Winkles J. A., The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting Nature Reviews Drug Discovery 2008 7 5 411 425 (Pubitemid 351619113)
77. Dogra C., Changotra H., Mohan S., Kumar A., Tumor necrosis factor-like weak inducer of apoptosis inhibits skeletal myogenesis through sustained activation of nuclear factor- B and degradation of MyoD protein Journal of Biological Chemistry 2006 281 15 10327 10336 (Pubitemid 43864571)
78. Kumar M., Makonchuk D. Y., Li H., Mittal A., Kumar A., Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) activates proinflammatory signaling pathways and gene expression through the activation of TGF-beta activated kinase 1 Journal of Immunology 2009 182 4 2439 2448
79. Mittal A., Bhatnagar S., Kumar A., Paul P. K., Kuang S., Kumar A., Genetic ablation of TWEAK augments regeneration and post-injury growth of skeletal muscle in mice American Journal of Pathology 2010 177 4 1732 1742
80. Harada N., Nakayama M., Nakano H., Fukuchi Y., Yagita H., Okumura K., Pro-inflammatory effect of TWEAK/Fn14 interaction on human umbilical vein endothelial cells Biochemical and Biophysical Research Communications 2002 299 3 488 493 (Pubitemid 35365656)
81. Lynch C. N., Wang Y. C., Lund J. K., Chen Y. W., Leal J. A., Wiley S. R., TWEAK induces angiogenesis and proliferation of endothelial cells Journal of Biological Chemistry 1999 274 13 8455 8459 (Pubitemid 29164634)
82. Kim S. H., Kang Y. J., Kim W. J., Woo D. K., Lee Y., Kim D. I., Park Y. B., Kwon B. S., Park J. E., Lee W. H., TWEAK can induce pro-inflammatory cytokines and matrix metalloproteinase-9 in macrophages Circulation Journal 2004 68 4 396 399 (Pubitemid 38470720)
83. Dogra C., Changotra H., Wedhas N., Qin X., Wergedal J. E., Kumar A., TNF-related weak inducer of apoptosis (TWEAK) is a potent skeletal muscle-wasting cytokine FASEB Journal 2007 21 8 1857 1869 (Pubitemid 46855631)
84. De Bleecker J. L., De Paepe B., Vanwalleghem I. E., M. Schrder J., Differential expression of chemokines in inflammatory myopathies Neurology 2002 58 12 1779 1785 (Pubitemid 34663578)
85. Burkly L. C., Michaelson J. S., Hahm K., Jakubowski A., Zheng T. S., TWEAKing tissue remodeling by a multifunctional cytokine: role of TWEAK/Fn14 pathway in health and disease Cytokine 2007 40 1 1 16 (Pubitemid 350088500)
86. Kamata K., Kamijo S., Nakajima A., Koyanagi A., Kurosawa H., Yagita H., Okumura K., Involvement of TNF-like weak inducer of apoptosis in the pathogenesis of collagen-induced arthritis Journal of Immunology 2006 177 9 6433 6439 (Pubitemid 44628862)
87. Tamada K., Shimozaki K., Chapoval A. I., Zhai Y., Su J., Chen S. F., Hsieh S. L., Nagata S., Ni J., Chen L., LIGHT, a TNF-like molecule, costimulates T cell proliferation and is required for dendritic cell-mediated allogeneic T cell response Journal of Immunology 2000 164 8 4105 4110 (Pubitemid 30215066)
88. Schneider K., Potter K. G., Ware C. F., Lymphotoxin and LIGHT signaling pathways and target genes Immunological Reviews 2004 202 49 66 (Pubitemid 39576904)
89. Hosokawa Y., Hosokawa I., Ozaki K., Nakae H., Matsuo T., TNFSF14 coordinately enhances CXCL10 and CXCL11 productions from IFN- -stimulated human gingival fibroblasts Molecular Immunology 2010 47 4 666 670
90. De Paepe B., De Keyzer K., Martin J. J., De Bleecker J. L., Alpha-chemokine receptors CXCR1-3 and their ligands in idiopathic inflammatory myopathies Acta Neuropathologica 2005 109 6 576 582 (Pubitemid 40974146)
91. Kim W. J., Kang Y. J., Koh E. M., Ahn K. S., Cha H. S., Lee W. H., LIGHT is involved in the pathogenesis of rheumatoid arthritis by inducing the expression of pro-inflammatory cytokines and MMP-9 in macrophages Immunology 2005 114 2 272 279
92. Tamada K., Tamura H., Flies D., Fu Y. X., Celis E., Pease L. R., Blazar B. R., Chen L., Blockade of LIGHT/LT and CD40 signaling induces allospecific T cell anergy, preventing graft-versus-host disease Journal of Clinical Investigation 2002 109 4 549 557 (Pubitemid 34171787)
93. Wu Q., Fu Y. X., Sontheimer R. D., Blockade of lymphotoxin signaling inhibits the clinical expression of murine graft-versus-host skin disease Journal of Immunology 2004 172 3 1630 1636 (Pubitemid 38116810)
94. Papadakis K. A., Zhu D., Prehn J. L., Landers C., Avanesyan A., Lafkas G., Targan S. R., Dominant role for TL1A/DR3 pathway in IL-12 plus IL-18-induced IFN- production by peripheral blood and mucosal CCR9+ T lymphocytes Journal of Immunology 2005 174 8 4985 4990
95. Bamias G., Martin C., Marini M., Hoang S., Mishina M., Ross W. G., Sachedina M. A., Friel C. M., Mize J., Bickston S. J., Pizarro T. T., Wei P., Cominelli F., Expression, localization, and functional activity of TL1A, a novel Th1-polarizing cytokine in inflammatory bowel Disease Journal of Immunology 2003 171 9 4868 4874 (Pubitemid 37310609)
96. Yamazaki K., Takahashi A., Takazoe M., Kubo M., Onouchi Y., Fujino A., Kamatani N., Nakamura Y., Hata A., Positive association of genetic variants in the upstream region of NKX2-3 with Crohn's disease in Japanese patients Gut 2009 58 2 228 232
97. Tremelling M., Berzuini C., Massey D., Bredin F., Price C., Dawson C., Bingham S. A., Parkes M., Contribution of TNFSF15 gene variants to Crohn's disease susceptibility confirmed in UK population Inflammatory Bowel Diseases 2008 14 6 733 737 (Pubitemid 351898055)
98. Bae E., Kim W. J., Kang Y. M., Suk K., Koh E. M., Cha H. S., Ahn K. S., Huh T. L., Lee W. H., Glucocorticoid-induced tumour necrosis factor receptor-related protein-mediated macrophage stimulation may induce cellular adhesion and cytokine expression in rheumatoid arthritis Clinical and Experimental Immunology 2007 148 3 410 418 (Pubitemid 46701026)
99. Patel M., Xu D., Kewin P., Choo-Kang B., McSharry C., Thompson N. C., Liew F. Y., Glucocorticoid-induced TNFR family-related protein (GITR) activation exacerbates murine asthma and collagen-induced arthritis European Journal of Immunology 2005 35 12 3581 3590 (Pubitemid 43025538)